Cullinan Therapeutics, Inc.
CGEM
$16.33
$0.181.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.07% | -0.20% | 27.76% | -44.44% | -1.79% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 2.60% | 1.32% | -1.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.18% | -21.31% | -0.88% | 15.83% | 15.35% |
| Change in Net Operating Assets | -153.74% | 10.80% | 32.40% | 333.58% | -137.19% |
| Cash from Operations | -20.82% | -3.34% | 35.99% | -33.49% | -17.83% |
| Capital Expenditure | -- | 71.05% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 44.69% | -66.78% | 26.27% | 45.09% | 130.55% |
| Cash from Investing | 44.76% | -66.77% | 26.20% | 45.09% | 130.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -46.85% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -46.85% | -- | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.68% | -149.17% | 895.70% | 39.61% | 66.72% |